Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis

Next Previous
Search
Trial Profile

An Open Label, Randomized, Multicenter, Comparative, Parallel Group Study of Rebif 44 Mcg Administered Three Times Per Week by Subcutaneous Injection, Compared With Avonex 30 Mcg Administered Once Per Week by Intramuscular Injection in the Treatment of Relapsing-remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon beta-1a (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms EVIDENCE
  • Sponsors EMD Serono; Merck Serono

Most Recent Events

  • 25 Sep 2018 Results of pooled data from 17 clinical trials and post-marketing surveillance, were published in the Advances in Therapy.
  • 27 Apr 2018 Results source (3318320) reports Pfizer as the funder for post-hoc analysis.Pfizer is the co-promoter/sub licensee of the primary drug along with Serono in USA.However, not sure in what way it was associated with this trial.Hence, I have not added it in association.
  • 24 Sep 2015 Post hoc results will be presented at ECTRIMS 2015, as per EMD Serono media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top